Combat Meth Enhancement looks likely
This article was originally published in The Tan Sheet
Executive Summary
Congressional staff expect the Combat Methamphetamine Enhancement Act to pass after the Senate and House agree to "minor technical corrections" in the legislation that requires retailers to comply with provisions of the Combat Methamphetamine Epidemic Act of 2006. Minor changes in the House bill passed Sept. 22 include tweaking phrasing, statutory citations, adding a statement to comply with the PAYGO Act and replacing 2009 with 2010 in the title. A Feinstein staffer said Senate members likely will approve the House version the week of Sept. 27. The bill requires retailers to self-certify compliance with Drug Enforcement Administration regulations concerning Combat Met Act retail sales provisions. It sets $5,000 penalties for noncompliance and prohibits distributors from delivering pseuodephedrine-containing OTCs to noncompliant stores. The Consumer Healthcare Products Association and the National Association of Chain Drugstores support the measure, which enhances regulations limiting sales of PSE without creating new restrictions on consumer access to the drugs (1"The Tan Sheet" Aug. 2, 2010, In Brief)
You may also be interested in...
Congress, Missouri Enhance Meth Enforcement
Efforts to further tighten controls on sales of OTC methamphetamine precursors get a boost nationwide from Congress and in Missouri from a state law
Energy and Commerce clears meth bill
The House Energy and Commerce Committee July 28 passes the Combat Methamphetamine Enhancement Act of 2009, H.R. 2923. The bill, which cleared the Energy and Commerce Subcommittee on Health days earlier, would require retailers of nonprescription pseudoephedrine products to self-certify compliance with existing Combat Meth regulations (1"The Tan Sheet" July 26, 2010). The legislation, which the Senate passed in S. 256 in June 2009, is expected to become law with support from both sides of the aisle and OTC and drug store trade groups
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.